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Abstract: The aim of this work was to produce and characterize cetyl palmitate-based solid 
lipid nanoparticles (SLN) containing insulin, and to evaluate the potential of these colloidal 
carriers for oral administration. SLN were prepared by a modiﬁ  ed solvent emulsiﬁ  cation-
evaporation method based on a w/o/w double emulsion. The particle size, zeta potential and 
association efﬁ  ciency of unloaded and insulin-loaded SLN were determined and were found 
to be around 350 nm, negatively charged and the insulin association efﬁ  ciency was over 43%. 
After oral administration of insulin-loaded SLN to diabetic rats, a considerable hypoglycemic 
effect was observed during 24 hours. These results demonstrated that SLN promote the oral 
absorption of insulin.
Keywords: insulin, solid lipid nanoparticles, oral administration, hypoglycemic effect, cetyl 
palmitate
Introduction
Insulin, a 51 amino acid peptide, has usually been administered parenterally in the 
treatment of diabetes mellitus (Beals and Kovach 1997). Unfortunately, injections 
are frequently painful, and can lead to low patient compliance. Consequently, oral 
delivery of insulin is expected to be an alternative route of administration to overcome 
compliance problems, decrease the contaminations risk and because it mimetizes 
in a better way the normal insulin pathway in the body after endogenous secretion 
(Hoffman and Ziv 1997).
Almost since the initial discovery of insulin alternative effective routes other than 
subcutaneous injection have been an elusive goal for many investigators (Carino and 
Mathiowitz 1999; Owens 2002). Oral administration of insulin has some limitations, 
including low oral bioavailability due to degradation in the stomach, inactivation 
and digestion by proteolytic enzymes in the luminal cavity, poor permeability across 
intestinal epithelium because of its high molecular weight and lack of lipophilic-
ity (Carino and Mathiowitz 1999). Consequently, various approaches have been 
examined to overcome the delivery problems of these peptides when orally adminis-
tered (Komplella and Lee 2001). Of these, carrier systems, such as liposomes (Kisel 
et al 2001), microemulsions (Celebi et al 2002), nanoparticles (Pan et al 2002), and 
microspheres (Kim et al 2002), have shown to improve the gastrointestinal absorp-
tion of peptide drugs. Also, hydrogels (Kim and Peppas 2003), azopolymer coating 
(Saffran et al 1991), site-speciﬁ  c drug delivery systems (Tozaki et al 1997), absorption 
enhancers (Ziv et al 1987), enzyme inhibitors (Yamamoto et al 1994) and modiﬁ  cation 
of chemical structure (Asada et al 1995) have shown similar effects.
Submicron-sized particles as oral protein delivery systems protect macromolecules 
against the harsh environment of the gastrointestinal tract (Lowe and Temple 1994) 
and enhance their transmucosal transport (Tobio et al 1998). This ability of nanopar-
ticles to enhance the transport of the encapsulated drugs has been attributed to International Journal of Nanomedicine 2007:2(4) 744
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different mechanisms such as mucoadhesion, nanoparticle 
internalization and permeation enhancing effect, depending 
on the colloidal composition. One of the advantages of 
nanoparticles, when administered orally, is that they can be 
absorbed transcellularly, not only through the membranous 
epithelial cells (M-cells) of the Peyer’s patches in the gut-
associated lymphoid tissue (GALT) (Clark et al 2001), but 
also through the gut enterocytes (Hussain et al 2001). The 
uptake of nanoparticles carrying proteins by enterocytes has 
been demonstrated to be a limited but capable process (des 
Rieux et al 2006). Enhancing mucoadhesion properties of 
nanoparticles are usually explored with efﬁ  ciency to pro-
mote the contact of proteins with the intestinal epithelium, 
increasing the concentration at the site of absorption (Garcia-
Fuentes, Torres et al 2005; Tobio et al 2000).
SLN were developed at the beginning of the 1990s as an 
alternative carrier system to the existing traditional carriers, 
such as emulsions, liposomes and polymeric nanoparticles 
(Muller and Lucks 1996). SLN made of solid lipids (lipids 
being solid at room and body temperatures) are submicron 
colloidal carriers (50–1000 nm) dispersed either in water 
or in an aqueous surfactant solution (Rawat et al 2006). By 
deﬁ  nition, the lipids can be highly puriﬁ  ed triacylglycerols, 
complexes acylglycerol mixtures or waxes (Souto and Müller 
2007). Compared to other particulate carriers, SLN show 
more advantages as drug delivery system, such as a good 
tolerability (Muller, Maaen et al 1996), biodegradation 
(Muller, Ruhl et al 1996), and the possibility of production 
on large industrial scale (Muller et al 2000). Also, it has been 
report that nanoencapsulation of proteins in lipid nanopar-
ticles has improved their bioavailability, prolonged their 
blood residence time and/or modiﬁ  ed their biodistribution 
(Garcia-Fuentes, Torres et al 2005; Muller et al 2006).
SLN show different degradation rates by the lipolytic 
enzyme pancreatic lipase as a function of their composition 
(lipid matrix, stabilizing surfactant) and it has been demon-
strated that the longer the fatty acid chains of the acylglycerols 
are, the slower is their degradation (Olbrich and Muller 1999). 
Type of surfactants can also inﬂ  uence degradation accelerating 
(eg, cholic acid sodium salt) or a hindering, degradation slow-
ing down effect, due to steric stabilization (eg, Poloxamer 
407) (Olbrich and Muller 1999). The longer the ethylene 
oxide chains are in the molecule, the more hindered is the 
anchoring of the lipase/co-lipase complex and consequently 
the degradation of the SLN. This knowledge can be used to 
adjust degradation of SLN and consequently drug release in 
a controlled way (Olbrich and Muller 1999). The wax cetyl 
palmitate seems to be suited to develop SLN intended for a 
controlled release of the incorporated active substances and for 
a frequent administration, due to a good in vitro degradation 
rate and a low in vivo toxicity (Lukowski et al 2000). Cetyl 
palmitate in SLN is arranged in a lamellar lattice structure and 
compounds can be stored between these layers (Lukowski et al 
2000). Finally, poloxamer 407 is a stabilizing surfactant very 
well tolerated in vivo (Muller et al 1997).
The purpose of this work was to develop a new nanopar-
ticulate carrier intended for the oral administration of pep-
tides. The new carrier is composed of a lipid core aimed to 
protect and to control the release of insulin.
Materials and methods
Materials
Wax cetyl palmitate was provided from Gattefossé (France). 
Polaxomer 407 (Lutrol® micro 127) was supplied by BASF 
(Germany). Acetonitrile LiChrosolv HPLC grade was obtained 
from Merck® (Germany) and triﬂ  uoroacetic acid (TFA) from 
Sigma (Portugal). Dichloromethane was from Pronalab 
(Portugal). Human zinc-insulin (lot RS0325, 7.0 mg lyophi-
lized human biosynthetic insulin per vial) was a generous gift 
from Lilly Portugal. Milli-Q-water was lab supplied.
Methods
Preparation of solid lipid nanoparticles
The method chosen for the preparation of nanoparticles 
was an adaptation of the w/o/w double emulsion technique 
(Garcia-Fuentes et al 2003; Zhang et al 2006). 200 mg of 
cetyl palmitate was dissolved in 4 mL of dichloromethane. 
7 mg of insulin was dissolved in 0.5 mL of HCL 0.1 M. The 
insulin solution was added to the lipid solution and then 
homogenized during 30 seconds in ultra-turrax T25 (IKA-
Labortechnik, Germany). The primary emulsion was poured 
into 25 mL of 2% poloxamer 407 solution and homogenized 
for additional 30 seconds. The solvent was removed and the 
emulsion was concentrated in rotavapor until ~10 mL.
Particle size analysis
Particle size was analyzed by photon correlation spectroscopy 
(PCS). Samples were diluted with Milli-Q-water to suitable 
concentration and the size measured with a Malvern Zetasizer 
5000 (Malvern Instruments, UK). All measurements were 
performed in triplicate.
Zeta potential
The electrophoretic mobility was measured by Laser 
Doppler Anemometry (LDA) using a Malvern Zetasizer International Journal of Nanomedicine 2007:2(4) 745
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5000 (Malvern Instruments, UK). Samples were diluted with 
Milli-Q-water having a conductivity adjusted to 50 μS/cm 
by addition of a 0.9% NaCl solution.
Transmission electron microscopy
To characterize the morphology of SLN these systems were 
observed by transmission electron microscopy (TEM). 
Samples were deposited on a grid, treated with uranil acetate 
and observed in a Zeiss EM 902A microscope.
Insulin association efﬁ  ciency
The association efﬁ  ciency (AE) was determined indirectly. 
The amount of insulin entrapped into SLN was calculated by 
the difference between the total amount used to prepare the 
systems and the amount of insulin that remained in the aque-
ous phase after SLN isolation. After preparation, aqueous 
SLN dispersions were centrifuged (UL 80 ultracentrifuge, 
rotor type 80Ti, Beckman Instruments, German) for 2 hours 
at 45000 rpm (corresponding to approx. 190000 × g). Insulin 
concentration in the supernatant was determined by HPLC 
(Sarmento et al 2006).
AE=
Total amount of insulin  Free insulin in supernatant
To
− 
t tal amount of insulin
×100
 
In vivo studies of insulin-loaded solid lipid 
nanoparticles in diabetic rats
All experiments were carried out in accordance to the 
Federation of European Laboratory Animal Science Asso-
ciation (FELASA) Guide for the Care and Use of Labora-
tory Animals and the European Union (Council Directive 
86/609/EEC).
Male Wistar rats with 200–250 g were housed in con-
trolled environmental conditions of temperature and relative 
humidity, maintained under 22 ± 2 °C and 45 a 65%, respec-
tively. The rats were fed with standard diet feed (Mucedola 
Top Certiﬁ  cate, Italy) and were provided tap water ad libitum. 
Lighting was on a standard 12 h on /12 h off cycle.
Diabetes was induced in rats by a single intraperitoneal 
injection of streptozocin (50 mg/mL in pH 4.5 citrate) at 
50 mg/kg. After two weeks, rats with fasted blood glucose 
levels above 250 mg/dL were used for experiments. These 
rats were fasted for 12 h before experiments and remained 
fasted for 24 h during the experiment, but had free access 
to water ad libitum.
SLN dispersions (1.0 mL) were administered intragastri-
cally by gavage needle to rats at insulin dose of 50 IU/kg, 
based on the total insulin content of the SLN. Control rats 
were similarly administered with equivalent volumes of 
insulin oral solution and empty SLN. Also, a control using 
subcutaneous insulin (2.5 IU/kg) was applied. Blood samples 
were taken from the tip of the tail vein. A 0.1 mL aliquot 
was collected before and 1, 2, 4, 6, 8, 10, 12, 14, 16 and 24 
hours after administration.
Pharmacological availability (PA) of peroral insulin-
loaded SLN was determined based on a 100% availability 
of the control solution administered subcutaneously to the 
diabetic rats at a dose of 2.5 IU of insulin/kg. Plasma glucose 
levels were plotted against time, and the area above the curve 
(AAC) below the 100% cut-off line was determined using 
the trapezoidal method.
PA=
AAC oral/Dose oral
AAC sc/Dose sc
×100
Plasma glucose level was determined using the Medisense 
Precision Xceed Kit, (Abbot, Portugal, range 10–600 mg/dL), 
and expressed as a percent of the baseline plasma glucose 
level. Results are shown as the mean of values (± SEM) of, 
at least, 6 animals. One-way analysis of variance (ANOVA) 
was used to evaluate treatment differences. If the group by 
each time interaction was signiﬁ  cantly different (P < 0.05), 
differences between groups were compared within a post-
hoc test (S-N-K). All statistical analyses were performed 
with the SPSS software package (SPSS for Windows 14.0, 
SPSS, Chicago, USA).
Results and discussion
SLN characterization
SLN were successfully produced by a modiﬁ  ed solvent 
emulsiﬁ  cation-evaporation method based on a w/o/w double 
emulsion. They are considered to be stable carriers for oral 
administration. Poloxamer 407 was used as surfactant in the 
aqueous phase when preparing the insulin-loaded SLN to 
increase their stability. Lipid nanoparticles may suffer aggre-
gation following incubation in gastric medium, whereas 
protective coating such as Poloxamer 407 or PEG diminished 
this phenomenon (Garcia-Fuentes et al 2003). Both unloaded 
and insulin-loaded SLN showed a homogenous size distribu-
tion with a mean diameter measured by PCS of 320 ± 26 nm 
and 361 ± 30 nm, respectively. Mean values of zeta potential 
were –8.0 ± 1.2 and –3.4 ± 0.2 mV for unloaded and insulin-
loaded SLN, respectively. The mean diameters conﬁ  rmed 
that the SLN produced are submicron colloidal carriers, 
suitable for enabling gastrointestinal absorption by M-cellsInternational Journal of Nanomedicine 2007:2(4) 746
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on Peyer’s patches. The zeta potential values are close to 
the electric neutrality, but it is possible to notice a slightly 
less negative value for insulin-loaded SLN probably due to 
the deposition on the surface of the SLN of some positively 
charged insulin. In fact, immediately after production, the 
pH of insulin-colloidal SLN dispersion was found to be 
3.1, lower than the isoelectric point of insulin which is 5.3 
(Brange 1987), responsible for the insulin positive charge.
The microscopic appearance and the structural charac-
terization of cetyl palmitate based SLN with insulin were 
performed using TEM (Figure 1). The particle size of 
unloaded and insulin-loaded SLN depicted in TEM images 
is in agreement with the results obtained with PCS. Fur-
thermore, the imaging analysis showed that these particles 
exhibit a spherical shape, and a dense lipid matrix without 
aggregation. The presence of insulin on the surface of SLN 
was not responsible for signiﬁ  cant agglomeration, predicting 
absence of aggregation after oral administration.
The AE of insulin in cetyl palmitate SLN was 43 ± 6%. 
This result means that approx. 56% of protein was in 
the dispersion medium, ie, solubilized by the surfactant 
molecules. It is noteworthy that being a hydrophilic molecule 
a much lower AE of insulin within the lipid matrix of SLN 
was expected. Nonetheless, the modiﬁ  ed w/o/w double emul-
sion method was shown to be a suitable production procedure 
to achieve relatively high encapsulation for insulin.
Determination of plasma glucose levels
Insulin-loaded SLN were administered orally to overnight 
fasted diabetic rats. The reduction of the initial glucose 
levels versus time after intragastric insulin-loaded SLN, 
insulin solution and subcutaneous administration of insulin 
is depicted in Figure 2. The mean plasma glucose baseline 
value was taken as 100% level.
After subcutaneous administration of insulin solution 
(2.5 IU/Kg), glycemia decreased signiﬁ  cantly by 45% after 
1 h to a maximal decrease of 55% after 2 h. This effect was 
maintained up to 4 h and control values were reached again 
after 6 h. Administration of intragastric aqueous insulin solu-
tion, at a dose of 50 IU/kg, was responsible for a minimum 
decrease, less that 20%, on the glycemia obtained after 6 h. 
Although the absence of physiologic effect after admin-
istration of insulin solution was expected, the absorption 
of a small fraction of insulin prior to its degradation could 
not be discarded. Insulin introduced in the lumen of the rat 
duodenum and colon was observed to be rapidly internalized 
by the epithelial cells and transferred through a transcytotic 
pathway via the Golgi apparatus to the interstitial space from 
which it reached the blood circulation (Ziv and Bendayan 
2000). This uptake of insulin was attributed through binding 
to speciﬁ  c insulin receptors in intestinal enterocytes. Then 
the exogenous insulin induces signiﬁ  cant decreases in plasma 
glucose levels which lasts for several hours (Bendayan et al 
1994; Ziv and Bendayan 2000).
Insulin-loaded SLN decreased glycemia by comparison 
with rats treated with oral insulin solution (Figure 2) and 
empty nanoparticles (Figure 3). This hypoglycemic effect 
was observed to occur in a biphasic way, with an initial 
peak between 4 and 8 h with a decrease of 25% of the initial 
glucose level and later after 12 h of assay prolonged for up 
to 24 h. This may be related with the typical biphasic drug 
release pattern with an initial burst and prolonged release 
from SLN, characterized by a microcrystal matrix structure 
(Hu et al 2002; Wissing et al 2004; Souto 2005). Such bipha-
sic pattern can originate an immediate release of insulin but 
also retain a signiﬁ  cant fraction of the drug entrapped into  Figure 1 TEM micrographs of (A) empty and (B) insulin-loaded SLN.
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the lipid matrix during prolonged time. Insulin released from 
SLN in the intestinal lumen is able to be directly internalized 
as discussed above, being the ﬁ  rst responsible for the physi-
ological effect. Then, after arrival to the appropriate sites for 
nanoparticle uptake in the posterior ileum (Jung et al 2000; 
Cui et al 2006), SLN are able to be absorbed (Garcia-Fuentes, 
Prego et al 2005), resulting in signiﬁ  cant hypoglycemic effect 
compared with oral insulin solution administration. After-
wards, it can be postulated that SLN undergo physiological 
degradation and the insulin enter into the blood circulation. 
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Figure 2 Percentage reduction of plasma glucose concentration in diabetic rats after administration of insulin-loaded SLN 50 IU/kg (c), subcutaneous injection of insulin 2.5 IU/
Kg (o) and oral insulin solution 50 IU/kg (). Data represents the mean ± SEM, n = 6 per group. *Statistically signiﬁ  cant differences from oral insulin solution (p < 0.05).
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Figure 3 Percentage reduction of plasma glucose concentration in diabetic rats after administration of an insulin-loaded SLN 50 IU/kg (c) and empty SLN ().Data repre-
sents the mean ± SEM, n = 6 per group. *Statistically signiﬁ  cant differences from negative empty nanoparticle (p < 0.05).International Journal of Nanomedicine 2007:2(4) 748
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It is generally accepted that nanoparticles with hydrophobic 
surfaces such as SLN, are taken up more extensively by the 
intestinal epithelium than those with hydrophilic surfaces 
(Eldridge et al 1990). Thus, the uptake of nanoparticles with 
lipid matrix is potentially facilitated. Also, the bioadhesive 
properties of lipids can lead to a gradient diffusion of insulin 
from the high concentrations in the SLN matrix towards the 
intestinal cells. The association of both mechanisms has been 
related with the prolonged physiologic affect of proteins after 
oral administration (Damge et al 1997; Lin et al 2007).
As shown in Table 1, the relative pharmacological 
bioavailability of insulin was 5.0% when administered into 
SLN and 1.6% in oral insulin solution. These overall results 
suggested that SLN could protect insulin from degradation 
and enhance intestinal absorption of insulin.
Conclusion
The attempts to develop an insulin-loaded SLN formulation 
for oral administration produced nanoparticles with spherical 
shape, slight negative zeta potential values and good asso-
ciation efﬁ  ciency. The plasma glucose levels of rats after 
oral administration of insulin-loaded SLN were lower that 
those obtain after administration of oral insulin solution and 
empty SLN up to 24 h. The solid matrix of SLN was able to 
partially protect insulin against chemical degradation in the 
gastrointestinal tract and to promote the intestinal absorp-
tion of insulin. In conclusion, SLN were found to be suitable 
carrier systems for the administration of insulin through the 
oral route. This study may contribute for the development 
of an optimized oral insulin formulation.
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